Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 J&J Pharmaceutical Sales up 14% in the Quarter | Contract Pharma

What are you searching for?

Sign in
Financial News

J&J Pharmaceutical Sales up 14% in the Quarter

COVID-19 Vaccine contributes $502 million in sales.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson
3Q Revenues: $23.3 billion (+11%)
3Q Earnings: $3.7 billion (+3%)
YTD Revenues: $69.0 billion (+15%)
YTD Earnings: $16.1 billion (+24%)
Comments: Pharmaceutical sales were $13.0 billion in the quarter, up 14% driven by DARZALEX for the treatment of multiple myeloma, STELARA, a biologic for immune-mediated inflammatory diseases, TREMFYA, a biologic for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis, ERLEADA, a next-generation androgen receptor inhibitor for prostate cancer, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA, long-acting, injectable atypical antipsychotics for the treatment of schizophrenia, and OPSUMIT for the treatment of pulmonary arterial hypertension. Also contributing to sales growth was the not-for-profit COVID-19 Vaccine (Ad26.COV2.S) with $502 million in sales. This growth was partially offset by declines in U.S. sales of REMICADE, a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, and INVOKANA for the treatment of type 2 diabetes. R&D expenses were up 21% in the quarter to $3.4 billion.
 
FDA Filings
In the quarter, the FDA approved INVEGA HAFYERA (paliperidone palmitate) the first and only twice-yearly treatment for adults with Schizophrenia.
 
XARELTO (rivaroxaban) plus aspirin was approved for expanded Peripheral Artery Disease (PAD) indication to include patients after Lower-Extremity Revascularization (LER).
 
UPTRAVI (selexipag) was approved for intravenous use in adult patients with Pulmonary Arterial Hypertension (PAH)
 
J&J submitted Emergency Use Authorization Amendment to the FDA to support a booster of its Single-Shot COVID-19 Vaccine.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters